SANGUINATE™
SANGUINATE™ is a biological therapy with 9 clinical trials. Historical success rate of 87.5%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
77.8%
7 of 9 finished
22.2%
2 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer
Clinical Trials (9)
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
All 9 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 9